COLORECTAL CANCER CHEMOPREVENTION: ASPIRIN, OTHER NSAID AND COX-2 INHIBITORS

2000 ◽  
Vol 70 (6) ◽  
pp. 452-455 ◽  
Author(s):  
Gabriel A. Kune
Keyword(s):  
Colorectal Cancer ◽  
Cancer Chemoprevention ◽  
Cox 2 ◽  
Cox 2 Inhibitors

COX-2 inhibitors and colorectal cancer chemoprevention

2002 ◽  
Vol 6 (2) ◽  
pp. 31-35 ◽  
Author(s):  
James Hok-Leung Tsu ◽  
Judy Wai-Chu Ho
Keyword(s):  
Colorectal Cancer ◽  
Cancer Chemoprevention ◽  
Cox 2 ◽  
Cox 2 Inhibitors

scholarly journals Chemoprevention in gastrointestinal physiology and disease. Anti-inflammatory approaches for colorectal cancer chemoprevention

2015 ◽  
Vol 309 (2) ◽  
pp. G59-G70 ◽  
Author(s):  
Alexandra M. Fajardo ◽  
Gary A. Piazza
Keyword(s):  
Colorectal Cancer ◽  
Natural Products ◽  
Molecular Mechanisms ◽  
Cancer Chemoprevention ◽  
Developed Countries ◽  
Chemopreventive Agents ◽  
Incidence And Mortality ◽  
Cox 2 ◽  
Anti Inflammatory ◽  
Cox 2 Inhibitors

Colorectal cancer (CRC) is one of the most common human malignancies and a leading cause of cancer-related deaths in developed countries. Identifying effective preventive strategies aimed at inhibiting the development and progression of CRC is critical for reducing the incidence and mortality of this malignancy. The prevention of carcinogenesis by anti-inflammatory agents including nonsteroidal anti-inflammatory drugs (NSAIDs), selective cyclooxygenase-2 (COX-2) inhibitors, and natural products is an area of considerable interest and research. Numerous anti-inflammatory agents have been identified as potential CRC chemopreventive agents but vary in their mechanism of action. This review will discuss the molecular mechanisms being studied for the CRC chemopreventive activity of NSAIDs (i.e., aspirin, sulindac, and ibuprofen), COX-2 inhibitors (i.e., celecoxib), natural products (i.e., curcumin, resveratrol, EGCG, genistein, and baicalein), and metformin. A deeper understanding of how these anti-inflammatory agents inhibit CRC will provide insight into the development of potentially safer and more effective chemopreventive drugs.

scholarly journals Oral cancer chemoprevention: COX-2 inhibitor a covenant

2021 ◽  
Vol 7 (4) ◽  
pp. 253
Author(s):  
Shashi Keshwar ◽  
Sonal Grover ◽  
Daya Shankar ◽  
Deependra Prasad Sarraf
Keyword(s):  
Oral Cancer ◽  
Cancer Survival ◽  
Cancer Chemoprevention ◽  
Premalignant Lesions ◽  
Treatment Modalities ◽  
Anti Cancer ◽  
Cox 2 ◽  
Anti Inflammatory ◽  
Cox 2 Inhibitors ◽  
The Relationship

<p>Oral cancer survival remains poor despite advancement in treatment modalities. In oral cancer and oral premalignant lesions, cyclooxygenase-2 (COX-2) is widely expressed and tends to be enhanced especially in high-risk oral lesions. Numerous researches suggests that the inflammation pathway of cyclooxygenase/prostaglandin E2 (PGE2) leads to the development and progression of a number of cancers, including oral squamous cell carcinoma (OSCC). With an emphasis on research data, this article discusses the relationship between inflammation and cancer, summarizes the use of anti-inflammatory agents COX-2 inhibitors for cancer chemoprevention and treatment, and explains the mechanisms underlying the anti-cancer effects of anti-inflammatory agents (COX-2 inhibitors).</p>

Effects of cyclooxygenase-2 (COX-2) inhibitors in colorectal cancer

2004 ◽  
pp. 177-187
Author(s):  
Christoph A. Maurer ◽  
Katharina M. Kessler
Keyword(s):  
Colorectal Cancer ◽  
Cyclooxygenase 2 ◽  
Cox 2 ◽  
Cox 2 Inhibitors

scholarly journals Use of Cox-2 Inhibitors and the Risk of Colorectal Cancer

2006 ◽  
Vol 163 (suppl_11) ◽  
pp. S37-S37
Author(s):  
P Coogan ◽  
L Rosenberg
Keyword(s):  
Colorectal Cancer ◽  
Cox 2 ◽  
Cox 2 Inhibitors

Gut-Restricted Selective Cyclooxygenase-2 (COX-2) Inhibitors for Chemoprevention of Colorectal Cancer

2021 ◽  
Author(s):  
Zhuming Zhang ◽  
Avijit Ghosh ◽  
Peter J. Connolly ◽  
Peter King ◽  
Thomas Wilde ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cyclooxygenase 2 ◽  
Cox 2 ◽  
Cox 2 Inhibitors

scholarly journals Role of Anti-inflammatory Drugs in the Colorectal Cancer

2019 ◽  
Vol 55 (3) ◽  
pp. 168-180
Author(s):  
Oumer Sada ◽  
Kemal Ahmed ◽  
Aliye Jeldo ◽  
Mensur Shafi
Keyword(s):  
Colorectal Cancer ◽  
Relative Risk ◽  
Meta Analysis ◽  
Data Sources ◽  
High Dose ◽  
Adjusted Relative Risk ◽  
Inflammatory Drugs ◽  
Cox 2 ◽  
Anti Inflammatory ◽  
Cox 2 Inhibitors

Objective: The objective of this review was to systematically review and synthesize evidence regarding benefits of using nonsteroidal anti-inflammatory drugs (NSAIDs) for the treatment of colorectal cancer (CRC). Data Sources: The data sources were MEDLINE, PubMed, NEJM, Google Scholar, and Google searches of references from relevant and eligible trials. Review Methods: We screened abstracts and full-text articles of identified references for eligibility and reviewed randomized controlled trials, cohort studies, and meta-analysis for evidence on benefits of using NSAIDs in CRC treatments. For all extracted data, completeness and relevance were checked. Results: The risk of any adenoma among frequent NSAID users was 26.8% vs 39.9% among placebo subjects who later used NSAIDs sporadically (adjusted relative risk = 0.62, 95% confidence interval [CI] = 0.39-0.98; P trend with NSAID use frequency = .03). Long-term use of aspirin reduces the risk of CRC. Aspirin also reduces the incidence of colon adenomas and mortality, especially when used for >10 years. Rofecoxib is associated with the reduction of CRC; however, it was associated with cardiovascular risk (with an overall unadjusted relative risk of 1.50 [95% CI = 0.76-2.94; P = .24]). Adenoma Prevention with Celecoxib trial shows that, for patients of all genotypes, the estimated cumulative incidence of one or more adenomas by year 3 was 59.8% for those randomized to placebo as compared with 43.3% for those randomized to low-dose (200 mg, twice daily) celecoxib (relative risk [RR] = 0.68; 95% CI = 0.59-0.79; P < .001) and 36.8% for those randomized to high-dose (400 mg, twice daily) celecoxib and 60.7% in placebo group (RR = 0.54; 95% CI = 0.46-0.64; P < .001). Conclusions: The use of COX-2 inhibitors both prior to and after diagnosis of CRC seemed to be mildly associated with the reduction in mortality of patients with CRC. Some literatures state that COX-2 inhibitors might play a synergistic role in adjuvant chemotherapy of FOLFOX regimen. Celecoxib was found to increase the radiosensitization of colon cancer cells.

Sign in / Sign up

Export Citation Format

Share Document